Tuesday, January 09, 2007 6:37:51 PM
I agree. I can hear the wise guys in the crowd now : " What JP needs is a good antiviral. "
From one of the slides , it looks like entecavir captured around 15-20% of the total nuke scrips by the end of the first year of sales. I'd be happy if Tyzeka shows a similar trajectory , but I haven't tried to figure out what the first-year sales figure would be for that scenario. Probably over $20 mill. , but maybe not that much more considering we're talking mostly U.S. sales until ex-U.S. ramps up.
To get to $20 mill. first-year sales we may be selling at a $50 or $60 mill. annual rate or more by the end of that first year (U.S.).
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
